These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 26811654)

  • 1. Personalized medicine in gastric cancer: Where are we and where are we going?
    Jácome AA; Coutinho AK; Lima EM; Andrade AC; Dos Santos JS
    World J Gastroenterol; 2016 Jan; 22(3):1160-71. PubMed ID: 26811654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.
    Jørgensen JT
    World J Gastroenterol; 2014 Apr; 20(16):4526-35. PubMed ID: 24782605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent updates of precision therapy for gastric cancer: Towards optimal tailored management.
    Joo MK; Park JJ; Chun HJ
    World J Gastroenterol; 2016 May; 22(19):4638-50. PubMed ID: 27217696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Companion diagnostics for the targeted therapy of gastric cancer.
    Yoo C; Park YS
    World J Gastroenterol; 2015 Oct; 21(39):10948-55. PubMed ID: 26494953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives.
    Pellino A; Riello E; Nappo F; Brignola S; Murgioni S; Djaballah SA; Lonardi S; Zagonel V; Rugge M; Loupakis F; Fassan M
    World J Gastroenterol; 2019 Oct; 25(38):5773-5788. PubMed ID: 31636471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug sensitivity testing platforms for gastric cancer diagnostics.
    Lau V; Wong AL; Ng C; Mok Y; Lakshmanan M; Yan B
    J Clin Pathol; 2016 Feb; 69(2):93-6. PubMed ID: 26567318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Alterations and Targeted Therapy in Gastric and Esophageal Adenocarcinoma.
    Pectasides E
    Clin Ther; 2016 Jul; 38(7):1589-99. PubMed ID: 27041412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies.
    Luis M; Tavares A; Carvalho LS; Lara-Santos L; Araújo A; de Mello RA
    World J Gastroenterol; 2013 Oct; 19(38):6383-97. PubMed ID: 24151357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced gastric cancer: Current treatment landscape and future perspectives.
    Digklia A; Wagner AD
    World J Gastroenterol; 2016 Feb; 22(8):2403-14. PubMed ID: 26937129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How Can Gastric Cancer Molecular Profiling Guide Future Therapies?
    Corso S; Giordano S
    Trends Mol Med; 2016 Jul; 22(7):534-544. PubMed ID: 27260398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular targeting to treat gastric cancer.
    Aoyagi K; Kouhuji K; Kizaki J; Isobe T; Hashimoto K; Shirouzu K
    World J Gastroenterol; 2014 Oct; 20(38):13741-55. PubMed ID: 25320512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and emerging therapies in unresectable and recurrent gastric cancer.
    Jou E; Rajdev L
    World J Gastroenterol; 2016 May; 22(20):4812-23. PubMed ID: 27239108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on metastatic gastric and esophageal cancers.
    Shah MA
    J Clin Oncol; 2015 Jun; 33(16):1760-9. PubMed ID: 25918288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic and metabolic prediction of response to therapy in gastric cancer.
    Aichler M; Luber B; Lordick F; Walch A
    World J Gastroenterol; 2014 Oct; 20(38):13648-57. PubMed ID: 25320503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Predictive diagnosis of HER2 in gastric adenocarcinoma].
    Daum O; Skálová A; Rozkos T; Laco J
    Cesk Patol; 2011 Oct; 47(4):160-3. PubMed ID: 22145214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Present and future molecular testing of lung carcinoma.
    Dacic S; Nikiforova MN
    Adv Anat Pathol; 2014 Mar; 21(2):94-9. PubMed ID: 24508692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
    Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
    J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data.
    Hescheler DA; Plum PS; Zander T; Quaas A; Korenkov M; Gassa A; Michel M; Bruns CJ; Alakus H
    Gastric Cancer; 2020 Jul; 23(4):627-638. PubMed ID: 32107691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of advanced gastric cancer.
    Price TJ; Shapiro JD; Segelov E; Karapetis CS; Pavlakis N; Van Cutsem E; Shah MA; Kang YK; Tebbutt NC
    Expert Rev Gastroenterol Hepatol; 2012 Apr; 6(2):199-208; quiz 209. PubMed ID: 22375525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.